Home Capital Results

Hyphens Pharma reports 49.7% higher 1QFY2022 NPAT of $3.2 mil

Felicia Tan
Felicia Tan5/13/2022 9:21 AM GMT+08  • 1 min read
Hyphens Pharma reports 49.7% higher 1QFY2022 NPAT of $3.2 mil
Revenue increased by 18.5% y-o-y to $39.2 million thanks to contributions from its three business segments and Novem.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Hyphens Pharma has reported net profit after tax (NPAT) of $3.2 million for the 1QFY2022 ended March, 49.7% higher than net profit of $2.1 million in the same period the year before.

Revenue increased by 18.5% y-o-y to $39.2 million thanks to contributions from its three business segments, as well as its newly-acquired subsidiary, Novem.

Gross profit increased by 23.9% y-o-y to $15.0 million, with gross profit margin improving 1.7 percentage points y-o-y to 38.4%.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now